Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology ...

An update from Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) is now available. Nanjing Leads Biolabs Co., Ltd. announced that five of its ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, ...

The poster presentation will be available on the Aptose website here.

The company will host a conference call and webcast for investors at 4:30pm ET following the ASH presentation. The abstract is now available on the ASH website and details are summarized below. A more ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation & immunology (I&I), today announced that it will ...

My experiences have demonstrated that business development combined with market analysis is the most powerful pairing for ...

UCSF researchers and clinicians presented innovative research and treatment strategies at the American Society of Radiation Oncology’s 2025 Annual Meeting in San Francisco, which ran from Sept. 27 to ...